lenacapavir


( Last Updated : August 29, 2022)
Generic Name:
lenacapavir
Project Status:
Pending
Therapeutic Area:
HIV-1 infection
Manufacturer:
Gilead Sciences Canada, Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0757-000
Call for patient/clinician input closed:

Details


Manufacturer Requested Reimbursement Criteria1:
For the treatment of human immunodeficiency virus type 1 (HIV-1) infection, in combination with other antiretroviral(s), in adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
For the treatment of human immunodeficiency virus type 1 (HIV-1) infection, in combination with other antiretroviral(s), in adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.